Regeneron Pharmaceuticals stock trades near its yearly high

Published on 09/23/2026 at 09:36 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Regeneron Pharmaceuticals stock reached USD 807.32 on September 22, 2026, below its USD 859.34 yearly high. July EPS beat consensus by USD 4.13.

REGN, US75811P1003, Illustration mit AI erstellt.

Regeneron Pharmaceuticals, Inc. (ISIN US75811P1003) traded at USD 807.32 on Nasdaq on September 22, 2026, after gaining USD 9.15 during the session. The price stood below the 52-week high of USD 859.34 and above the 52-week low of USD 541.00, placing the stock closer to its yearly peak than its floor.

July results set the benchmark

The latest reported quarter delivered EPS of USD 14.29 in Q2 2026, beating the consensus estimate of USD 10.16 by USD 4.13. Revenue reached USD 4.29 billion in Q2 2026, compared with expectations of USD 3.82 billion, while revenue increased 16.7 percent from the year-earlier quarter, according to MarketBeat on September 22, 2026.

The comparison matters because Q2 2025 EPS was USD 12.81. Regeneron's Q2 2026 net margin was 27.86 percent, giving investors a measurable profitability reference alongside the double-digit revenue increase.

Analyst targets cluster near price

MarketBeat reported on September 22, 2026, that Wells Fargo raised its target from USD 700.00 to USD 750.00 while keeping an equal-weight rating, and Cantor Fitzgerald increased its objective from USD 750.00 to USD 795.00 while maintaining an overweight rating. Morgan Stanley also lifted its target from USD 730.00 to USD 758.00 and retained an equal-weight view, according to MarketBeat.

The reported consensus price target was USD 802.18, below the September 22 price of USD 807.32. That spread of USD 5.14 makes the valuation debate more immediate: the stock price was already slightly above the cited average target, even as the Q2 earnings comparison remained favorable.

Regeneron presents on September 23

Regeneron is scheduled to present at Bernstein Insights: Healthcare Leaders and Disruptors, the third annual Healthcare Forum, at 10:30 a.m. EDT on September 23, 2026, according to Newsquawk on September 22, 2026. The event gives the market a dated checkpoint for management commentary after the Q2 revenue and EPS beat.

Stock remains below its high

Regeneron stock closed at USD 807.32 on Nasdaq on September 22, 2026. Its market capitalization was USD 83.12 billion, with average volume of 829,892 shares and a reported session volume of 244,562 shares, according to MarketBeat data dated September 22, 2026.